Interferon gamma and tumour necrosis factor alpha induce a synergistic antiproliferative response in human Ewing's sarcoma cells in vitro.
Three human cell lines derived from Ewing's sarcoma (RM-82, VH-64, and WE-68) were investigated to establish the influence of recombinant human interferon gamma (rhIFN gamma) and tumour necrosis factor alpha (rhTNF alpha) on cell proliferation and survival and to characterize IFN gamma and TNF alpha receptor expression. Incorporation of [3H]thymidine into cells was inhibited by rhIFN gamma after 24 h of incubation. Half-maximal inhibition was observed with 10-80 U/ml rhIFN gamma. A maximal effect (50%-70% inhibition of cell proliferation) was achieved by treatment of cells with 250 U/ml rhIFN gamma. The influence of rhTNF alpha on proliferation was found to differ among cell lines and varied with the concentration and the duration of exposure of cells to this cytokine. In WE-68 and VH-64 cells [3H]thymidine incorporation was not affected by rhTNF alpha up to 2000 U/ml after 96 h of incubation, whereas in RM-82 cells the incorporation was inhibited by 35% after 48 h of incubation with 100 U/ml rhTNF alpha. However, all cell lines showed a synergistic antiproliferative response to the combination of rhIFN gamma and rhTNF alpha after 24 h of incubation. The human recombinant cytokines interleukin(IL)-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-6 and granulocyte/macrophage-colony-stimulating factor, tested alone and in combination with rhIFN gamma and rhTNF alpha, had no influence on cell proliferation. Binding studies in the cell lines with 125I-rhIFN gamma revealed a dissociation constant (Kd) of 160-306 pM and approximately 8000-13,500 receptors/cell. Binding experiments with 125I-rhTNF alpha indicated 430-1250 receptors/cell with Kd ranging from 13 pM to 162 pM. These data indicate that, among various cytokines, only IFN and TNF alpha are capable of potently reducing Ewing's sarcoma cell growth in vitro. Our data suggest that IFN alone or in combination with TNF alpha may be useful in the design of novel strategies in Ewing's sarcoma therapy.
van Valen
F
F
Abt. für Pädiatrische Hämatologie und Onkologie, Westfälische-Wilhelms-Universität, Münster, Germany.
Winkelmann
W
W
Burdach
S
S
Göbel
U
U
Jürgens
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011994:Recombinant Proteins; D012512:Sarcoma, Ewing / Q000473:pathology* / Q000628:therapy; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*
D016207:Cytokines; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma